An Inquiry into Weight Loss Medications and Legal Responsibilities: A Review of Current Litigation Trends
Aug. 14, 2023 | Share This Post:
A critical analysis of GLP-1 lawsuits for Ozempic & similar drug complications. Understand legal precedents & patient rights. Within the dynamic realm of therapeutic interventions for obesity and type 2 diabetes, a novel category of pharmacological agents has garnered attention for their beneficial outcomes and has simultaneously prompted concerns due to their adverse effects. The initiation of legal proceedings has recently been observed as a response to significant health complications attributed to the class of Glucagon-like Peptide-1 (GLP-1) agonist medications, including Ozempic, Wegovy, Mounjaro, and Rybelsus. This discourse seeks to examine the legal ramifications of these litigations, elucidating the accountability...
Continue ReadingComprehensive Analysis of the Ongoing Roundup Litigation Landscape
Aug. 11, 2023 | Share This Post:
Navigating the Complex Terrain of Roundup Litigation The protracted litigation surrounding Roundup, the widely used herbicide, is entering a pivotal phase as Monsanto/Bayer prepares for a series of jury trials. The imminent trials represent a crucial juncture, embodying both the possibility of significant rewards for plaintiffs and the inherent risks of the litigation process. In the forthcoming months, Monsanto is scheduled to confront a sequence of jury trials in the plaintiff-oriented Court of Common Pleas in Philadelphia, with the first trial commencing on October 5, 2023. Additional trials will unfold into 2024 in Cobb County, Georgia, where Monsanto is yet...
Continue ReadingKenvue’s Denied Appeal: Legal Impact in Tylenol Autism Cases
Aug. 04, 2023 | Share This Post:
Kenvue’s Denied Appeal: Legal Impact in Tylenol Autism Lawsuits In a pivotal development within the pharmaceutical industry, U.S. District Judge Denise Cote recently delivered a ruling with significant implications for Kenvue Inc., formerly part of Johnson & Johnson. The ruling denied Kenvue the ability to immediately appeal a decision that allows lawsuits claiming their product, Tylenol, could potentially cause autism in children when taken by mothers during pregnancy. This decision underscores the evolving legal challenges facing pharmaceutical companies and highlights the importance of scientific evidence in product liability cases. Key Points: Legal Implications of Denying Immediate Appeal: Kenvue’s request for...
Continue ReadingParaquat Litigation Progresses Towards Daubert Hearing and Trial Set for October
Jul. 31, 2023 | Share This Post:
Paraquat Litigation Advances: Daubert Hearing and October Trial Insight The litigation process involving the herbicide Paraquat advances as key procedural hearings are scheduled. Notably, the legal teams involved have concluded their detailed briefings on two significant motions—the Daubert motion and the motion for partial summary judgment. A Daubert hearing, a critical juncture in the proceedings, is slated to commence on August 21, 2023, where expert testimonies will be pivotal. Key Points: Daubert Hearing and Trial Dates Set: A crucial Daubert hearing for the Paraquat litigation is scheduled to begin on August 21, 2023, with the outcome expected to significantly affect...
Continue ReadingParaquat: Heading to Daubert Hearing and October Trial
Jul. 31, 2023 | Share This Post:
The parties have completed their briefing of two important substantive motions including Daubert and partial summary judgment. They are now poised to begin arguments and obtain testimony at the Daubert hearing which begins on August 21, 2023. These briefs have been filed under seal except for a single “roadmap brief” filed by defendants on June 9th arguing the science does not support the general causation opinions of Plaintiffs’ experts. Judge Rosenstengl issued an order on July 28th which, among others, requires Plaintiffs’ expert Dr. Martin Wells to appear and be subject to direct and cross-examination by respective counsel. The Order...
Continue ReadingAdvancements in Acetaminophen Litigation and the Approach to Daubert Hearings
Jul. 29, 2023 | Share This Post:
Advancements in Acetaminophen Litigation and Daubert Hearing Strategies The landscape of the ongoing acetaminophen litigation has seen a series of favorable rulings for the plaintiffs, as overseen by Judge Cote. Her judicial decisions have consistently dismissed the preemptive defenses posited by defendants, including two motions from Walmart and one from Johnson & Johnson (J&J). The motions aimed to invoke federal preemption, which were not only rebuffed once but in J&J’s case, the attempt to secure an interlocutory appeal to the Second Circuit Court of Appeals was also denied. In a strategic move, the plaintiffs’ leadership team has taken steps to...
Continue ReadingThe Legal Landscape Post-LTL Bankruptcy Dismissal and Implications for Talcum Powder Litigation
Jul. 29, 2023 | Share This Post:
The trajectory of talcum powder litigation has reached a pivotal juncture following the recent developments involving LTL Management LLC, a subsidiary formed by Johnson & Johnson (J&J) ostensibly to address the influx of lawsuits related to talcum powder. The second attempt by LTL to seek bankruptcy protection was dismissed by the Third Circuit Court of Appeals on grounds of insufficient “good faith,” since the entity was deemed not to be in genuine “financial distress,” particularly given its backing by J&J’s up to $61 billion funding agreement. The subsequent bankruptcy petition by LTL, filed just two hours after further setbacks in...
Continue ReadingTylenol Litigation: Getting Closer to the Daubert Motions
Jul. 29, 2023 | Share This Post:
Judge Cote has largely ruled in plaintiffs’ favor to date on most of the defendants’ initial motions — e.g., denying Walmart’s preemption motion twice and J&J’s preemption motion, and various other motions to dismiss claims on other grounds. Most recently she denied J&J’s motion seeking her permission to file an immediate (interlocutory) appeal from her preemption ruling to the Second Circuit Court of Appeals. Plaintiffs’ leadership have filed amended master complaints against J&J and separately, against the various retail chain defendants who had manufactured and sold their own house brands of acetaminophen (i.e., Walmart, and other major retailers). These master complaints...
Continue ReadingTalcum Powder Lawsuits: LTL’s Second Bankruptcy Dismissed
Jul. 29, 2023 | Share This Post:
Talcum Powder Lawsuits: LTL’s Second Bankruptcy Dismissed! The future of talcum powder litigation is at a crucial turning point. LTL Management LLC (the subsidiary J&J created to limit exposure to talcum powder lawsuits by seeking bankruptcy protection in October 2021) shockingly filed for bankruptcy a second time on April 4, 2023. This new filing came after the Third Circuit Court of Appeals dismissed LTL’s initial filing on January 30, 2023 as lacking the requisite “good faith” because LTL was clearly not in “financial distress.” The primary factor, among others, was that LTL was supported by a J&J-created funding agreement valued...
Continue ReadingPotential Firefighting Foam Water District Settlement
Jul. 26, 2023 | Share This Post:
On June 2, 2023, Dupont and Chemours announced an AFFF/PFAS proposed class action settlement potentially covering approximately 7,000 public water systems for $1.185 billion, and in July filed a motion seeking MDL Judge Gergel’s preliminary approval for a proposed class action settlement. Three weeks later on June 22nd, 3M announced a similar AFFF/PFAS proposed class action settlement potentially covering a pool of approximately 6,000+ public water systems for a net present value amount of between $10.3 billion and $12.5 billion, to be paid over 13 years. Here too plaintiffs’ counsel and 3M’s counsel filed a motion in July in the...
Continue Reading